NCT07383857招募中不适用
PULSAR Radiotherapy Plus Anti-PD-1 Therapy in Metastatic Abdominopelvic Tumors
Zhen Zhang1 个研究点 分布在 1 个国家目标入组 103 人开始时间: 2025年5月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 103
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
This study evaluates hypofractionated radiotherapy combined with PD-1 inhibitor-based systemic therapy in patients with metastatic solid tumors. Eligible patients will be enrolled into three cohorts according to tumor type: metastatic hepatocellular carcinoma, metastatic renal cell carcinoma, and metastatic urothelial carcinoma. The study aims to assess the safety and therapeutic efficacy of combining localized radiotherapy with immunotherapy, with or without cohort-specific systemic agents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the time of enrollment, with no restriction on sex.
- •Histologically, cytologically, or radiologically confirmed metastatic abdominopelvic malignancy, including hepatocellular carcinoma, renal cell carcinoma, or urothelial carcinoma.
- •No more than 10 metastatic lesions, and the radiotherapy treatment plan indicates that radiotherapy can be safely delivered.
- •At least one measurable lesion is present.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Determined by a multidisciplinary team (MDT) to require active antitumor treatment.
- •Adequate bone marrow, liver, renal, and coagulation function as demonstrated by laboratory tests performed within 7 days prior to the first dose of study treatment; no blood transfusion, blood products, granulocyte colony-stimulating factor (G-CSF), or other hematopoietic growth factors are permitted within 7 days prior to laboratory testing.
- •Voluntary participation with written informed consent provided, and willingness to comply with the study treatment protocol and scheduled visits.
排除标准
- •Absolute neutrophil count (ANC) <1.5 × 10⁹/L, or platelet count <100 × 10⁹/L (or <80 × 10⁹/L in patients with liver metastases), or hemoglobin <9 g/dL; blood transfusion within 2 weeks prior to enrollment to meet eligibility criteria is not permitted.
- •Serum total bilirubin >1.5 × the upper limit of normal (ULN), or >2.5 × ULN in patients with liver metastases.
- •Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 × ULN, or >5 × ULN in patients with liver metastases.
- •Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m².
- •Clinically significant electrolyte abnormalities as determined by the investigator.
- •Active gastrointestinal diseases, including but not limited to gastric or duodenal ulcers, ulcerative colitis, or active bleeding from unresected tumors; or other conditions judged by the investigator to carry a risk of gastrointestinal bleeding or perforation; or a history of gastrointestinal perforation or fistula that has not fully healed after surgical treatment.
- •History of arterial thrombosis or deep vein thrombosis within 6 months prior to enrollment, or evidence or history of bleeding tendency within 2 months prior to enrollment, regardless of severity.
- •Stroke or transient ischemic attack within 12 months prior to enrollment.
- •Significant cardiac disease within 6 months prior to enrollment, including congestive heart failure, acute myocardial infarction, severe or unstable angina, or coronary artery bypass grafting; or New York Heart Association (NYHA) class II or higher heart failure; or left ventricular ejection fraction (LVEF) <50%.
- •Presence of a clinically detectable second primary malignancy at screening, or a history of another malignancy within the past 5 years, except for adequately treated early-stage non-melanoma skin cancer, carcinoma in situ of the cervix, superficial bladder cancer (non-muscle-invasive tumors, carcinoma in situ, or T1 tumors), or early-stage thyroid cancer.
- •Known clinically significant liver disease, including but not limited to hepatitis B virus (HBV) infection with positive HBV DNA (≥1 × 10⁴ IU/mL), hepatitis C virus (HCV) infection with positive HCV RNA (≥1 × 10³ IU/mL), or cirrhosis.
- •Pregnant or breastfeeding women, women of childbearing potential with a positive pregnancy test prior to first dosing, or participants (or their partners) unwilling to use effective contraception during the study period.
- •Any clinical or laboratory abnormality or compliance issue that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
- •Presence of severe psychological or psychiatric disorders.
研究组 & 干预措施
Experimental group
Experimental
干预措施: pulsed radiotherapy (Radiation)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: 1 year
次要结局
未报告次要终点
研究者
Zhen Zhang
Director
Fudan University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.NCT07410520The First Affiliated Hospital with Nanjing Medical University50
招募中
2 期
Radiometabolic Therapy (RMT) with 177Lu PSMA in PSMA PET/CT positive advanced/metastatic tumours: a basket trial (LUBASKET)2024-519346-75-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.83
尚未招募
2 期
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast CancerNCT07256964Henan Cancer Hospital216
招募中
2 期
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPCNCT07332247Sun Yat-sen University94
尚未招募
2 期
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsNCT07360743UNICANCER275